NCT05517616View on ClinicalTrials.gov

The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

April 20, 2023

Conditions
Pharmacokinetics
Interventions
DRUG

[14C ]APG-2575

orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT05517616 - The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects | Biotech Hunter | Biotech Hunter